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This is the last in a series of articles highlighting the delivery of
‘‘packages of care’’ for mental health disorders in low- and middle-
income countries. Packages of care are combinations of treatments aimed
at improving the recognition and management of conditions to achieve
optimal outcomes.
Introduction
Attention-deficit hyperactivity disorder (AD/HD) is a chronic,
pervasive developmental disorder that, although usually diagnosed
in childhood, spans the preschool to adult years. The most recent
version of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR) defines the disorder using the core
features of age-inappropriate hyperactivity, impulsivity, and
inattention (Box 1) [1]. The 10th edition of the International
Classification of Diseases (ICD-10) provides operational criteria for
the similar, but more severe and narrowly defined hyperkinetic
disorder (HKD) [2]. We have used the term AD/HD throughout
this paper because most of the published literature relates to the
broader concept of AD/HD rather than to HKD.
A rapidly expanding body of literature from low- and middle-
income countries (LMICs) largely refutes the notion that AD/HD
is a ‘‘Western’’ concept, although cultural factors clearly influence
illness perceptions and help-seeking behavior [3–7]. A systematic
review and meta-regression analysis of 102 studies from all
continents concluded that the worldwide pooled prevalence of
AD/HD is 5.3%, and that the geographic variability between
AD/HD prevalence estimates is best explained by the methodo-
logical characteristics of the studies [8].
A strong body of evidence from high-income countries (HICs)
suggests that AD/HD is a neurobiological syndrome with complex
genetic factors primarily implicated in its etiology. Although
individual risk alleles identified by molecular genetic studies
increase the risk of AD/HD only slightly, the mean estimate of
total heritability is just under 80% [9]. A wide range of social
determinants significantly influence the symptomotology of AD/
HD in HICs. These include low socioeconomic status, low
parental education, family conflict, parental mental disorder,
severe early deprivation, and institutional upbringing [9–11]. The
involvement of these multiple determinants in the symptomatology
of AD/HD is consistent with the hypothesis that AD/HD is an
etiologically heterogeneous, final common pathway disorder that is
influenced by genes, environment, and gene–environment inter-
actions. Other nongenetic causes of AD/HD identified in HICs
are factors that affect early brain development, such as perinatal
stress, low birth weight, prenatal smoking and alcohol use,
obstetric complications, head injury, epilepsy, and HIV/AIDS
[9–11]. The mediating and moderating influence of these variables
on the development of AD/HD amongst children in LMICs is
less well researched and does not always match with that seen in
HICs [11].
The Evidence on the Treatment of AD/HD
Detection
Accurate detection and diagnosis of AD/HD is crucial for the
effective management of individuals with the disorder [12–14].
Two structured approaches are available to detect and diagnose
AD/HD: clinical diagnostic interviews and rating scales (Table 1).
The only clinical diagnostic interview that we are aware has been
assessed in LMICs is the Diagnostic Interview Schedule for
Children (DISC-IV) [15], which has been validated for use in
China [16] and for Xhosa-speaking South Africans [17]. In
China, the test-retest reliability of the AD/HD component was
excellent for the version of the interview given to parents
(k=0.81) and poor for the version given to adolescents (k=0.25).
Similarly, for the South African Xhosa version of the DISC-IV
the parent version resulted in substantial reliability (k=0.56)
whereas the youth version resulted in poor reliability (k=0.23).
Although systematic reviews have investigated the numerous
rating scales developed to diagnose AD/HD in HICs [12–14],
only a few scales have been developed for use in LMICs. In
Brazil, the test-retest reliability of a scale for use by teachers based
on DSM-III-R diagnostic criteria ranged from 0.56 to 0.70 [18],
and the diagnostic performance of the Child Behavior Checklist
Attention problem scale resulted in moderate areas under the
curve (AUC=0.78) [19].
Medication
The efficacy of pharmacological interventions for the
treatment of AD/HD in HICs is well established (Table 1)
[20–23]. Although there are few studies on medication for AD/
HD from LMICs, efficacy data from studies conducted in HICs
a r el i k e l yt ob ea p p l i c a b l et ot h e se settings. Pharmacologic
agents used in the treatment of AD/HD include the psycho-
stimulants (methylphenidate or amphetamine), atomoxetine,
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[24,25]. The psychostimulants, which have been used clinically
for more than 50 years, are supported by the most robust
efficacy and safety data and are available as affordable generic
immediate and sustained release formulations [25]. Methylphe-
nidate has been established as an effective short-term treatment
for school-age children and adults with AD/HD, and there are
some data, albeit sparse, that support its efficacy in preschoolers
[26,27]. The short-term efficacy of atomoxetine, a newer
medication, is also supported by numerous large-scale clinical
trials, although direct comparison studies with the psychostim-
ulants have demonstrated greater treatment effect sizes for
methylphenidate [28,29]. Also, the psychostimulants are less
expensive than atomoxetine and more likely to be available in
LMICs. Longer-term open label studies in HICs for methyphe-
nidate and atomoxetine support the efficacy and safety of both
these medications [30,31].
Before the introduction of atomoxetine, tricyclic antidepressants
(TCAs) were a common alternative to the psychostimulants.
Table 1. The evidence in support of AD/HD treatment.
Intervention Evidence from HICs Evidence from LMICs
Screening and
diagnosis
N Test-retest reliability of the Diagnostic Interview Schedule for Children
(DISC-IV) [15]
N Systematic review of measures used to diagnose AD/HD in preschool
children [14]
N Summary of evidence-based assessment of AD/HD [13]
N Ten-year review of rating scales for assessing AD/HD [12]
N Test-retest reliability of the Chinese [16] and Xhosa [17] version
of the DISC-IV.
N Test-retest reliability of a scale developed for use by teachers to
assess AD/HD in Brazilian schools [18]
N Assessment of the Child Behavior Checklist-Attention problem
scale in Brazil [19]
Methylphenidate N Systematic reviews [20–23] —
Behavioral therapy N Review of evidence-based psychosocial treatments for AD/HD [47]
N Meta-analyses of the efficacy of behavioral therapy for AD/HD [48]
—
Cognitive behavioral
therapy
N Review of cognitive training for AD/HD children [50]
N Review of cognitive, cognitive behavioral, and neural-based
Interventions [49]
—
Family therapy N Meta-analysis of parent involvement in treating AD/HD [52]
N Cochrane Review of family therapy for AD/HD [51]
N Evaluation of Parent Management Training in Iran [53]
N Evaluation of effectiveness of providing parents with training
about attention enhancing tasks and child behavior in India [54]
doi:10.1371/journal.pmed.1000235.t001
Box 1. DSM-IV-TR Criteria for Attention Deficit
Hyperactivity Disorder and International
Classification of Diseases 10 Criteria for
Hyperkinetic Disorder
According to the DSM-IV-TR, to satisfy the criteria for AD/
HD, a patient must manifest six or more symptoms of
inattention or hyperactivity-impulsivity that have persisted
for at least six months ‘‘to a degree that is maladaptive and
inconsistent with developmental level.’’ Examples of
symptoms of inattention include often having difficulty in
sustaining attention in tasks or play activities, being easily
distracted by extraneous stimuli, and often being forgetful
in daily activities. Examples of symptoms of hyperactivity–
impulsivity include often fidgeting with hands or feet or
squirming in seat, often talking excessively, and often
having difficulty awaiting turn. In addition, some of the
symptoms causing impairment must have been present
before the age of seven years, some impairment from the
symptoms must be present in two or more settings, there
‘‘must be clear evidence of clinically significant impairment
in social, academic, or occupational functioning,’’ and the
symptoms should ‘‘not occur exclusively in the course of a
Pervasive Developmental Disorder, Schizophrenia, or other
Psychotic Disorder and are not better accounted for by
another mental disorder’’ [1].
According to the ICD-10, to satisfy the criteria for
hyperkinetic disorder, a patient must demonstrate ‘‘abnor-
mality of attention, activity and impulsivity at home, for the
age and developmental level of the child,’’ as evidenced at
least three of a set of attention problems, plus at least three
of a set of activity problems, plus at least three of a set of
impulsivity problems. In addition, the patient must dem-
onstrate ‘‘abnormality of attention at school or nursery (if
applicable), for the age and developmental level of the
child,’’ as evidenced by at least two of a set of attention
problems and at least three of a set of activity problems.
Also, there must be ‘‘directly observed abnormality of
attention or activity,’’ which is ‘‘excessive for the child’s age
and developmental level.’’ Finally, the child must not meet
criteria for selected other conditions, onset must be before
the age of seven years, the duration must be at least six
months, and the IQ must be above 50 [2].
Summary Points
N Attention-deficit/hyperactivity disorder (AD/HD) is a
multidimensional disorder that, although commonest
in childhood and adolescence, can be diagnosed across
the age span. Worldwide prevalence is about 5%.
N An appropriate package of treatment for AD/HD in low-
and middle-income countries (LMICs) should include
screening of high-risk groups, psychoeducational inter-
ventions with caregivers, methylphenidate, and behav-
ioral interventions.
N Strategies to facilitate the delivery of effective interven-
tions in LMICs should increase demand for services,
access to AD/HD interventions, and the capacity of
health care teams, as well as improve recognition of AD/
HD, develop community-based and practice-based
programs, and address the impact of AD/HD on other
health and social outcomes.
N Interventions to address AD/HD should be part of a
more comprehensive package of services for mental
disorders.
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drug classes and the association of TCAs with troublesome side
effects, potential cardiotoxicity, and the risk of death in the
event of overdose has taken TCAs out of favor [21,24,25]. The
evidence base for other medications in the treatment of AD/HD is
weak.
The most frequent troublesome side effects associated with the
psychostimulant medications are reduced appetite, weight loss,
and sleep difficulties [32,33]. Compared to the pyschostimulants,
atomoxetine has less-pronounced effects on appetite and sleep but
is more likely to be associated with gastrointestinal upset [34]. Both
the pyschostimulants and atomoxetine may be associated with
slight increases in heart rate and blood pressure. Finally, the
psychostimulants are controlled substances and concerns exist
regarding the risk of pyschostimulant misuse and drug diversion.
However, there is no clear evidence that pyschostimulant-treated
AD/HD children abuse prescribed medication when they are
appropriately diagnosed and carefully monitored [35].
Children treated with medication require careful clinical
monitoring for side effects, clinical response, adherence, treatment
acceptability, and dose adjustment. Treating clinicians must have
a proficient understanding of the pharmacokinetic and pharma-
codynamic properties of these medications, the potential for
adverse events, and strategies for addressing emergent side effects.
Medication monitoring should include: a baseline assessment
followed by regular assessment of symptoms, function, side effects,
adherence, and the emergence of comorbid disorders or other
medical conditions; measurement of height, weight, blood
pressure, and pulse; and provision of psychoeducation that
addresses emerging questions or concerns from the patient or
family.
There is limited empirical evidence (all from HICs) to inform
the duration of treatment with pharmacological agents in AD/
HD. Six- and eight-year follow-up data from the Multimodal
Treatment Study of Children with AD/HD (MTA) failed to
provide support for long-term medication treatment where care
was provided in community settings without ongoing careful
titration and monitoring [36]. Decisions about continuing or
discontinuing medication should be individualized, with periodic
discontinuations to assess need and benefit.
Finally, decisions regarding the use of pharmacological therapy
should be informed by the level of impairment, symptom severity,
availability of appropriately trained health personnel and support,
accessibility to monitoring and follow-up services, acceptability to
patient and the family, and cost. Pharmacologic treatment is not
indicated if symptoms are mild, if there is minimal impairment or
an unclear diagnosis, if there are inadequate services for close
monitoring and follow-up, or if the use of medication is
unacceptable to the patient or family.
Structured Psychotherapies
Two of the largest studies of psychotherapies for the treatment
of AD/HD ever conducted are the New York-Montreal Study and
the MTA study [37–41]. In the New York-Montreal Study, 103
children with AD/HD (ages 7–9), who did not have comorbid
conduct or learning disorders and who had responded to
methylphenidate were allocated randomly to three groups for
two years: (1) methylphenidate treatment alone; (2) methylpheni-
date combined with multimodal psychosocial treatment that
included parent training and counseling, academic assistance,
psychotherapy, and social skills training; or (3) methylphenidate
plus attention control treatment that excluded specific aspects of
the psychosocial intervention. Individual assessments were con-
ducted on outcome measures such as academic and emotional
status [39] and symptomatic improvement [40]. This study found
no significant difference between the combined-treatment groups
and the medication-only group. In the MTA study, 579 children
aged 7.0 to 9.9 years with AD/HD were randomly assigned to
four treatment groups (medication, behavioral treatment, com-
bined treatment, and community care) [38]. The authors
concluded that after the 24-month follow-up, medication was
superior over the other individual treatment options and that there
was no significant difference between the combined treatment and
medication-only [41]. However, further analysis of the data
concluded that patients with AD/HD and either comorbid
disorders [42–44] or psychosocial stressors [45,46] did benefit
from adjunctive psychosocial interventions (parent training and
behavioral interventions).
Several reviews have investigated whether psychosocial inter-
ventions are effective for treating children and adolescents with
AD/HD (Table 1). A systematic literature review [47] and a meta-
analysis that investigated 174 AD/HD treatment studies conclud-
ed that behavioral treatment is highly effective [48]. Reviews of
cognitive-behavioral [49,50] and family therapy [51,52] interven-
tions have yielded promising but inconclusive findings.
We were not able to locate any randomized controlled trials
addressing the efficacy of structured psychotherapies for the
treatment of AD/HD in LMICs. However, an Iranian study
[53] reported that Parent Management Training (eight sessions,
once a week for 1.5 hours) improved the behavior of 15 children
with AD/HD and the general health of their parents. Similarly,
an Indian study investigated the effectiveness of a program
providing five training sessions to ten parents of boys aged
6–10 years with AD/HD. The training, which addressed
attention-enhancing tasks and child behavior principles and
techniques, had significant effects on the behavior of the children,
and parent-reported study habits, pro-social behavior, and
academic performance [54].
Delivery of Effective Interventions
Interventions to Increase Demand for Services
Similarly to the other disorders discussed in this series, stigma
and a lack of awareness about mental health problems are
important contributors to a relatively low demand for services for
AD/HD in LMICs. In the case of AD/HD, however, the salience
of these factors is magnified because AD/HD is most common
among children and adolescents, an age group in which stigma
and lack of awareness are particularly evident [55]. Among
populations where stigma is high and knowledge levels low, efforts
should be directed in the first instance to increasing general
awareness and recognition of the disorder (Table 2). Once this
goal has been achieved, attention may need to be focused on
minority groups, inattentive type AD/HD, girls with AD/HD,
and adult AD/HD. While specialists in mental health, education,
and pediatrics should take a leading role in reducing stigma and
increasing awareness, the potential contribution of community-
based advocacy groups should not be ignored. School is a
particularly important setting for stigma reduction and informa-
tion raising activities. While we were unable to locate any reports
that evaluated awareness or recognition programs for AD/HD
specifically, Hoven et al. [56] assessed children, parents, and
teachers before and after an awareness program to determine
changes in knowledge, attitudes, and understanding of mental
health in nine countries including Azerbaijan, Brazil, China,
Georgia, Russia, and Uganda. The authors reported a positive
change in awareness in all the countries and an increased
willingness to discuss emotional problems freely.
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Step How By Whom In What Settings
Increasing
demand for
services
N Develop and implement mental health literacy programs
for the general public, government, non-government and
private sectors focused on increasing awareness and
understanding of common mental disorders and addressing
the stigma associated with them.
N Develop and implement specific awareness programs for
common child mental disorders specifically targeting the
general public and community organizations that interface
with children and adolescents.
N Target awareness programs to increase recognition of
specific subgroups once services are available and
accessible to the most prevalent groups.
N Child and adolescent mental
health specialists
N Educational psychologists
N Community pediatricians
N Mental health advocacy groups
N Schools [56]
N Faith-based organizations
N Primary health care services
N Social development offices
N Traditional healing practices
N General practices
N Pediatric and psychiatric services
Increasing
access to
AD/HD
interventions
N Create the necessary policy and legislative environment [57]
N Ensure access to methylphenidate and other medications
N Provide affordable and equitable services and referral
pathways [9]
N Develop services in rural settings
N Encourage affordable local public transport to improve
accessibility of services
N Provide selected interventions in school settings [58]
N Integrate child and adolescent mental health services with
primary and traditional care systems
N For adolescents, provide interventions ‘youth friendly’
settings
N Offer incentives for child and adolescent mental health
specialists to work outside of regional centers
N Establish shorter and more direct training pathways to
registration as a sub-specialist
N Child and adolescent mental
health specialist teams
N Community pediatric teams
N General adult psychiatrists in
regions without access to child
and adolescent mental health
services
N Primary mental health nurses
N Mental health advocacy groups
N Politicians
N Service planners and managers
N Pharmacists
N Rural community clinics
N Village health teams
N General practice clinics
N Community pediatric services
N Schools
N Youth clubs and centers
Increasing
the capacity
of health
care teams
N Provide training, supervision, liaison and consultation for
all providers or potential providers of services for people
with AD/HD [9,58]
N Strengthen formal links between services based in cities
and those in rural areas, partly using tele-psychiatry if
feasible [57]
N Establish shorter and more direct training pathways to
registration as a sub-specialist
N Child and adolescent mental
health specialist teams
N Specialist and sub-specialist
training institutions
N Rural community clinics
N Village health teams
N General practice clinics
N Community pediatric services
N General adult psychiatric services
Improving
recognition
of AD/HD
N Increase capacity of health care teams
N Improve access to valid and reliable AD/HD rating
instruments
N Improve access to psychometric testing to evaluate
overall intelligence and exclude specific learning
disorders
N Child and adolescent mental
health specialist teams
N General adult psychiatrists in
regions without access to child
and adolescent mental health
services
N Educational psychologists
N Community pediatricians
N Schools
N Primary health care services
N Social development offices
N Traditional healing practices
N General practices
N Community pediatric practices
N Institutional and alternative child-
care settings
Adapting
AD/HD
treatments
to increase
acceptability
or reduce
costs
N Integrate mental health services into the education and
health care systems [57]
N Provide culturally acceptable and language-appropriate
care [9]
N Reduce racial/ethnic disparities in access to child and
adolescent mental health services
N Institute group psychotherapy interventions, including
parent management training and social skills/anger
management groups
N Increase access to less stigmatizing, longer-acting stimulant
medications that do not need to be taken during school
hours
N Develop nurse-led, specialist-supervised AD/HD clinics
N Consider motivational enhancement therapy for
adolescents
N Child and adolescent mental
health specialist teams
N Community paediatric teams
N Child psychiatric nurse specialists
N Primary mental health nurses
and social workers
N Educators and school counsellors
N Schools
N Pre-schools
N Community clinics
N Community centers
N Youth clubs/centers
N General practice clinics
N Community pediatric services
N Child and adolescent mental
health care services
Developing
community-
based
programs
N Introduce classroom-based behavioral strategies
N Encourage caretakers to use behavioral techniques and
improve communication between them and children with
the disorder
N Persuade leaders of community-based programs to link
people with the disorder with services that provide
appropriate interventions
N Institute early childhood development programs
N Child and adolescent mental
health specialist teams
N Community pediatric teams
N General adult psychiatrists in
regions without access to child
and adolescent mental health
services
N Primary mental health nurses and
social workers
N Educators and school counselors
N Schools
N Pre-schools
N Community clinics
N Community centers
N General practice clinics
N Rural outreach teams and village
health teams
N Community pediatric services
N Child and adolescent mental
health services
PLoS Medicine | www.plosmedicine.org 4 February 2010 | Volume 7 | Issue 2 | e1000235Interventions to Increase Access to Interventions
Important elements of a strategy for increasing access include
advocacy for the development of new, or the revision of existing,
policy and legislative frameworks that ensure the promotion of
mental health and the development of services that are accessible,
affordable, appropriate, and acceptable to the children, families,
and communities they are meant to serve (Table 2). Other
important elements include ensuring that evidence-based, cost-
effective treatments are both accessible and consistently available
and that appropriately trained, skilled, and experienced staff are
available [57]. A crucial aspect of access to effective treatment for
AD/HD is access to the psychostimulants and other pharmaco-
logical agents for which there is evidence of effectiveness. This may
require that child and adolescent psychiatrists and pharmacists
attend financial committees and other managerial structures to
ensure that the appropriate psychopharmacological agents are
available and affordable, that financing is sustainable, and that
health and supply systems are reliable. Clearly, the inclusion of
methylphenidate in national and transnational lists of essential
drugs is crucial in facilitating such circumstances.
Interventions to Increase the Capacity of Health Care
Teams
People with AD/HD may interface with health providers in
many settings. Thus, a broad range of health care providers may
be potential targets of capacity development activities. Depending
on the context, providers may include child and adolescent mental
health specialists, pediatricians, general psychiatrists, general
medical service providers, and other nonphysician health provid-
ers, particularly those who work closely with children and
adolescents. Opportunities for continual learning and support
through mentorship, supervision, and continuing education should
be built into capacity development initiatives. Training content
should be tailored to the needs of target groups but should be
based on an understanding of AD/HD as a chronic, pervasive
disorder requiring a holistic, multisectoral approach to manage-
ment and should be provided as part of a broader curriculum that
addresses the comorbid mental health issues associated with AD/
HD. Ensuring that capacity development initiatives are accessible
and available to target groups can be a challenge in any context,
and how training is delivered may have to be tailored to best meet
the needs of the recipients. General psychiatrists in rural areas
might benefit from telepsychiatry to improve their prescribing
practices, for example. Similarly, educators might benefit from
continuing education seminars that focus on the identification of
children with AD/HD and on classroom interventions, and
pediatric primary health care nurses might benefit from supervised
clinical practice followed by direct access to a nursing or medical
specialist consultation.
Interventions to Improve Recognition of AD/HD
Strategies to improve recognition of AD/HD should be
implemented only once access to services has been ensured and
health care providers have sufficient capacity to respond to an
increased demand for interventions. There are three aspects to
improving recognition: (1) awareness of the risk factors for AD/
HD and the identification of persons at risk; (2) screening of
persons at risk for ADHD; and (3) determination of a diagnosis of
AD/HD. As mentioned above, there are many useful clinical
instruments and rating scales for both screening and assessment of
AD/HD. Depending on the context, informal health services,
schools, faith-based organizations, and other community-based
groups can be invaluable in the early recognition of risk factors for
potential mental health problems including AD/HD. Where
available, psychometric testing may also help to assess the extent to
which low levels of intellectual functioning or deficits in academic
skill contribute to the presentation. Clearly, such instruments,
rating scales, and tests are most likely to produce optimum benefits
when they are administered by people with the necessary skill,
training, and facility in the language of the individuals who are
being assessed.
Interventions to Adapt Treatments to Increase
Acceptability or Reduce Costs
Both methylphenidate and amphetamine, the best-studied and
most cost-effective medicines for AD/HD, are available in long-
acting preparations that require once daily dosing. Such dosing is
often preferable to multiple daily dosing, particularly for school-
aged children and adolescents, and should be made available
where possible. Psychosocial interventions may be delivered in
either individual or group format and may be offered in various
settings including schools. Individual-level interventions, while
having advantages over group-level interventions, are not always
feasible because of the shortages of appropriately trained staff.
While group-level interventions are implemented in many settings
in both LMICs and HICs, there is a dearth of evaluations of such
interventions, a gap that begs filling.
Integration of child and adolescent mental health services into
the education and/or primary health care system can also increase
the acceptability and affordability of AD/HD treatments [58].
Step How By Whom In What Settings
Encouraging
practice-
based
programs
N Collaborative care N Specialists in mental health
N Non-professional health care
workers
N Primary health care settings
Addressing
the impact
of AD/HD on
other health
and social
outcomes
N Deliver services for people with AD/HD together with
services for other disorders
N Provide AD/HD services throughout the life span
N Provide interventions for specific problems that are
associated with AD/HD, such as anger management,
family conflict, scholastic deficiencies and substance
misuse
N Child and adolescent mental
health specialist teams
N Community pediatric teams
N General adult psychiatrists in
regions without access to child
and adolescent mental health
services
N Mental health service managers
and planners
N All settings where AD/HD
interventions are delivered
doi:10.1371/journal.pmed.1000235.t002
Table 2. Cont.
PLoS Medicine | www.plosmedicine.org 5 February 2010 | Volume 7 | Issue 2 | e1000235There are numerous models for integrating mental health services
into community and primary care that require the development of
continuous care pathways linking different levels of the health
system. One example is the development of nurse-led but
specialist-supervised clinics. The strategy adopted will be highly
dependent on the resources and infrastructure available in a
particular setting.
Interventions to Develop Community-Based Programs
The establishment of community-based initiatives in partner-
ship with formal health services allows the development of a
continuous network of care and support for children with AD/HD
and their families. Such care and support is essential to achieving
and maintaining optimal functioning and ameliorating the
disability associated with AD/HD. Schools, where most children
spend most of their time, can be the cornerstone of such programs.
Educators can be helped to implement classroom-based behavioral
interventions such as token economy systems in which children are
rewarded immediately for desirable behavior with tokens that can
be exchanged later for a reward, or response cost systems in which
a ‘‘fine’’ is imposed for bad behavior. Other interventions that
could be introduced include increasing teacher-to-child classroom
ratios and breaking the school day into brief academic assignments
interspersed with brief periods of physical exercise [58]. Commu-
nity-based organizations can also be used to deliver parenting
interventions and support for families and caregivers, to provide
gatekeeper functions and public mental health education, and to
assist with accessing medications for which there is evidence of
effectiveness.
Interventions to Encourage Practice-Based Programs
Collaborative care programs that are specific to a particular
disorder (as opposed to more general strategies such as the
integration of mental health care into the primary health care
system) have been successfully implemented for depression [59].
Furthermore, there is evidence that with appropriate diagnostic
and pharmacological training, both general practitioners and
pediatricians can apply this intervention effectively in HICs for
AD/HD [60,61]. However, we were not able to locate any studies
in which practice-based programs to address AD/HD have been
implemented and evaluated in LMICs.
Interventions to Address the Impact of AD/HD on Other
Health and Social Outcomes
AD/HD is frequently comorbid with other mental health
problems and is associated with a range of negative health and
social outcomes. Thus, services for people with AD/HD should
not be delivered in isolation from services for other disorders. Also,
because most children with AD/HD will retain the diagnosis into
adulthood or continue to be deleteriously affected by the
symptoms associated with AD/HD, it is crucial that interventions
are not terminated in adolescence, as frequently occurs. By
continuing to receive intervention, the probability of long-term
adverse consequences of the disorder is reduced. Finally, it is
important to offer interventions for selected specific problems that
are associated with AD/HD, such as anger management, family
conflict, scholastic deficiencies, and substance misuse.
Packages of Care for AD/HD in LMICs
AD/HD is a common developmental disorder that affects
individuals throughout their lives and across all cultural contexts,
and is associated with considerable social, psychological, and
economic adversity. Recognition of the disorder can be improved
by the use of screening instruments, some of which have been
shown to have adequate psychometric properties in LMICs.
Although there are few studies from LMICs that address the
effectiveness of methylphenidate, the consistent and strong effects
that have emerged from HICs suggest that this drug will be
effective universally. In addition, although the evidence for
structured psychotherapies is mixed, there is sufficient justification
to include behavioral interventions in a package of care for AD/
HD in LMICs (Table 3). However, given that most people
worldwide with AD/HD will not receive interventions from a
mental health specialist such as a psychiatrist or psychologist, it is
essential that efforts to deliver this package of care in LMICs are
not dependent on such specialists. There are risks associated with
such an approach. For example, the quality of the interventions
may be less than would have been the case if they were delivered
by specialists. However, such risks need to be weighed against the
certainty that services will be less accessible if they are delivered by
specialists. Finally, it is crucial that this package of care for AD/
HD form part of a more comprehensive package of services in
which other disorders are also addressed.
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